Fennec Pharmaceuticals Inc. (FRX.TO)
Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
At close: 03:52PM EST
| Previous Close | 12.97 |
| Open | 13.43 |
| Bid | 13.11 x 0 |
| Ask | 13.35 x 0 |
| Day's Range | 13.27 - 13.43 |
| 52 Week Range | 5.15 - 13.49 |
| Volume | |
| Avg. Volume | 2,041 |
| Market Cap | 348.478M |
| Beta (5Y Monthly) | 0.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.82 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Fennec Pharmaceuticals Inc.
Reported its financial results for the fiscal quarter ended September 30. Net loss for the three months ...
- GlobeNewswire
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
~ In September 2022, FDA Approved PEDMARK®, the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Tumors ~ ~ Initiated U.S. Commercial Launch of PEDMARK® in October 2022 ~ ~ Closed $25 Million in Funding from Petrichor to Support the U.S. Commercialization of PEDMARK®, With the Potential to Access an Additional $20 Million Prior to December 31, 2023 ~ RESEARCH TRIANGLE PARK, N.C., Nov. 11
- Simply Wall St.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC): Are Analysts Optimistic?
Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) is possibly approaching a major achievement in its business, so we would...
© 2022 Yahoo. All rights reserved.
